Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Lipocine Inc (LPCN)

Lipocine Inc (LPCN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 28,918
  • Shares Outstanding, K 5,316
  • Annual Sales, $ -2,850 K
  • Annual Income, $ -16,350 K
  • 60-Month Beta 1.05
  • Price/Sales -10.15
  • Price/Cash Flow N/A
  • Price/Book 1.24
Trade LPCN with:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/24
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year -0.68
  • Growth Rate Est. (year over year) +147,011.76%

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.80 +38.56%
on 03/25/24
7.15 -26.29%
on 04/11/24
+1.01 (+23.71%)
since 03/19/24
3-Month
3.20 +64.69%
on 03/07/24
7.15 -26.29%
on 04/11/24
+1.50 (+39.79%)
since 01/19/24
52-Week
2.31 +128.13%
on 10/30/23
7.15 -26.29%
on 04/11/24
+0.09 (+1.64%)
since 04/19/23

Most Recent Stories

More News
Lipocine: Q3 Earnings Snapshot

Lipocine: Q3 Earnings Snapshot

LPCN : 5.27 (-3.13%)
Lipocine to Present at the Cantor Fitzgerald Global Healthcare Conference

/PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on treating Central Nervous System (CNS) disorders, today announced that Dr....

LPCN : 5.27 (-3.13%)
Lipocine: Q2 Earnings Snapshot

Lipocine: Q2 Earnings Snapshot

LPCN : 5.27 (-3.13%)
Lipocine Announces Financial Results for the Second Quarter Ended June 30, 2023

/PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on treating Central Nervous System (CNS) disorders, today announced financial...

LPCN : 5.27 (-3.13%)
LPCN 1148 Phase 2 Study Meets Primary Endpoint in Patients with Cirrhosis

/PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on treating Central Nervous System (CNS) disorders by leveraging its...

LPCN : 5.27 (-3.13%)
Lipocine to Present at H.C. Wainwright Annual Neuropsychiatry Virtual Conference

/PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on treating Central Nervous System (CNS) disorders by leveraging its...

LPCN : 5.27 (-3.13%)
Lipocine to Present LPCN 1148 and LPCN 1144 at the EASL Congress 2023

/PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on treating Central Nervous System (CNS) disorders by leveraging its...

LPCN : 5.27 (-3.13%)
Positive Topline Clinical Results Support Streamlined Development Pathway for LPCN 1154, Lipocine's Oral Candidate for Rapid Relief of Depression

/PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), today announced positive topline results from a pilot clinical PK bridge study of LPCN 1154 (oral brexanolone)...

LPCN : 5.27 (-3.13%)
Lipocine: Q1 Earnings Snapshot

Lipocine: Q1 Earnings Snapshot

LPCN : 5.27 (-3.13%)
Lipocine Announces Financial Results for the First Quarter Ended March 31, 2023

/PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on treating Central Nervous System (CNS) disorders by leveraging its...

LPCN : 5.27 (-3.13%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Lipocine, Inc. is a specialty pharmaceutical company. It develops pharmaceutical products for use in men's and women's health. The Company's lead product candidate, LPCN 1021, is in Phase 3 and is targeted to treat symptoms of low testosterone for men in need of testosterone replacement therapy. Its...

See More

Key Turning Points

3rd Resistance Point 5.72
2nd Resistance Point 5.62
1st Resistance Point 5.45
Last Price 5.27
1st Support Level 5.18
2nd Support Level 5.08
3rd Support Level 4.91

See More

52-Week High 7.15
Fibonacci 61.8% 5.30
Last Price 5.27
Fibonacci 50% 4.73
Fibonacci 38.2% 4.16
52-Week Low 2.31

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar